NZ609568A - Modified release pharmaceutical compositions of desvenlafaxine - Google Patents

Abstract

A modified release pharmaceutical composition comprising Desvenlafaxine Benzoate (O-desmethylvenlafaxine benzoate), one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein Desvenlafaxine Benzoate is characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 ± 0.2 degrees. Also disclosed are specific modified release pharmaceutical compositions wherein concentration and AUC of the modified release composition are independent of food effect.

Description

MODIFIED RELEASE CEUTICAL COMPOSITIONS OF DESVENLAFAXINE Field Of The Invention: This t invention relates to modified release pharmaceutical compositions comprising Desvenlafaxine and a process for preparation f.

Background Of The Invention: nin—norepinephrine reuptake inhibitors (SNRIS) are a class of antidepressant drugs used in the treatment of major depression and other mood disorders. They are also used to treat anxiety disorders, obsessive-compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), chronic neuropathic pain. fibromyalgia syndrome (FMS), and for the relief of menopausal symptoms.

Serotoninenorepinephrine reuptake inhibitors (SNRIS) include but not limited to venlafaxine, Desvenlafaxine, milnacipran, duloxetine, sibutramine, levomilnacipran and sibutramine.

Desvenlafaxine is nin—norepinephrine reuptake inhibitors and chemically, Desvenlafaxine is chemically named (i)[2-(dirnethylamino)—1—(4- hydroxyphenyl)ethyljcyclohexanol, is a major metabolite of axine and has been shown to inhibit norepinephrine and serotonin uptake. Desvenlai'axine, which can also be referred to as O-Desmethylvenlafaxine or hylvenlafaxine, is ented by the following structural formula: (3:3 v" ‘ \- ~" - ¢.- Lil-g. , we" "wk "", "1.11.1".w" N‘w * "I 2' g 1 .«if ). a." l l ‘ "\V J 55"} \"r\ ./..«~"t O~desmethyl venlafaxine is a major metabolite of axine and has been shown to inhibit norepinephrine and nin uptake.

Desvenlafaxine was exemplified as a fumarate salt in US. Pat. No. 4.535,]86. However, the fumarate salt of ethyl—venlafaxine has unsuitable physicochemical and permeability characteristics. O-desmethyl—venlafaxine is also exemplified as a free base in International Patent Publication No. WO 00/3255 5.

US. Pat. No. 6,673,838 disclose ent lline forms of Desvenlafaxine Succinate mainly Form I, II, III and IV. r it ses amorphous form of Desvenlai‘axine Succinate. US. Pat. No. 7,820,716 discloses Form V and Form F of Desvenlafaxine Succinate.

Different salts of Desvenlafaxine have been disclosed in the literature. Succinate salt (US. Pat. No. 6,673,838 and US Patent Application No. 20040106576); formate (US.

Pat. No.7,001,920); hydrochloride (AU Patent Application No. 20080218997): citrate, maleate, mesylate, mandelate, quinic acid salt and tartrate (WO 2010008735); phosphate (WO 2009136756); D-glucuronate and orotate (WO 2009095431); oxalate, Benzoate and lactate (WO 2009053840); saccharinate (WO 2009017813).

Salt formation provides a means of altering the physicochemical and resultant biological characteristics of a drug without modifying its chemical structure. A salt form can have a ic influence on the properties of the drug. The selection of a le salt is partially dictated by yield, rate and quantity of the crystalline structure. In addition, hygroscopicity, stability, solubility and the process profile of the salt form are important considerations. The identification of a salt form that exhibits a suitable combination of properties can be difficult.

The Succinate monohydrate form of Desvenlafaxine has been incorporated into an extended release hydro-gel tablet, which reduces adverse effects such as nausea, vomiting, diarrhea, and abdominal pain. Formulations describing the use of hydroxypropyl cellulose (HPMC) as the el matrix have been described in US. Pat. No. 7,291,347.

US Patent Application No 20050175698 provides an c coated multiparticulate form of Desvenlafaxine that reduces undesirable characteristics associated with Desvenlafaxine and the hydrogel formulation thereof. These Desvenlafaxine multiparticulates are composed of Desvenlafaxine Succinate, Desvenlafaxine e, or combinations thereof. Advantageously, this formulation also allows more convenient dosing to patients who have difficulty swallowing solid foods.

US Patent Application No 20100210719 bes stable amorphous O— desmethylvenlafaxine Succinate solid dispersions with one or more ceutically acceptable carriers.

US Patent Application No 20100330172 discloses matrix controlled-release phannaceutical ation comprising Desvenlafaxine Suceinate, having an MMD of between about 5 micrometer and about 100 micrometer and matrix rate—controlling pharmaceutically acceptable r.

US Patent Application No 20110046231 provides pharmaceutical composition comprising a solid state form of ethylvenlafaxine salt and one or more pharmaceutically acceptable excipients, wherein the salt of O-desmethylvenlafaxine is an oxalate salt, a Benzoate salt or a lactate salt.

US Patent Application No 20070014859 ses superbioavailable DVS (O— desmethylvenlafaxine Succinate) sustained release composition comprising a core containing at least DVS and a water ble filler in an oral dosage unit having a delayed release of at least about one hour and a sustained release over multiple hours to provide a total release of greater than about 85% within about 12 to about 14 hours.

While there are many compositions available to reduce side effects of conventional dosage forms, still there remains a need to develop a controlled release composition of Desvenlafaxine.

Objective Of The Invention: The main object of invention is to provide modified release ceutical composition of Desvenlafaxine.

W0 40577 Another object of invention is ed release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable exeipientts) thereof.

Another object of invention is modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein d50 particle size of Desvenlafaxine is upto about 80 microns.

Another object of invention is modified release ceutical ition comprising lafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable exeipient(s), wherein composition releases about 75% of lafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.

Another object of invention is modified release pharmaceutical composition comprising lafaxine, one or more e ing agent(s) and one or more pharmaceutically acceptable ent(s), wherein d50 particle size of Desvenlafaxine is upto about 80 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.

Another object of invention is modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically able excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more phannaceutically acceptable exeipient(s).

Another object of invention is modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being r coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable exeipient(s), such that dso particle size of Desvenlafaxine upto about 80 microns.

PCT/IBZOIZ/051761 Another object of invention is modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being r coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.

Another object of invention is modified release pharmaceutical composition comprises a matrix core sing Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), n dso particle size of Desvenlafaxine is upto about 80 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 09% NaCl in water at 100 rpm.

Summary Of The ion: The present invention provides modified release pharmaceutical compositions sing Desvenlafaxine and a process for preparation thereof and their use in medicines. The invention relates to modified release pharmaceutical compositions comprising Desvenlafaxine te, one or more release ing agent(s) and one or more ceutically acceptable excipient(s) f. which is ivalent to extended release composition of Desvenlafaxine Succinate in a bioavailability study in humans.

Further, Cmax and AUC of the modified release composition comprising lafaxine Benzoate are independent of food effect.

Detailed Description Of The Invention: The present invention relates to provide modified release pharmaceutical composition of Desvenlafaxine and a process for preparation thereof. 2012/051761 It will be understood that, for the purposes of invention, Desvenlafaxine may be used in the form of base, pharmaceutically acceptable salt(s) or omer(s) or polymorph(s) thereof.

The term "pharmaceutically acceptable salts" refers to salts comprise but not limited to which are prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids, Suitable xic acids include inorganic and organic acids such as acetic, benzenesulfonic, benzoic, camphorsulfonic. citric, ethenesulfonic, , furnaric, ic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, , malic, mandelic, methane-sulfonic, mucic, nitric, . panlothenic, phosphoric, succinic, sulfuric. tartaric. p-toulenesufonic acids and the like. Preferably. Desvenlafaxine is in the salt form. More preferably Desvenlafaxine salt is Benzoate, Succinate, glutarate & palmitate.

In another embodiment, Desvenlafaxine Benzoate is in crystalline form or in amorphous form or a mixture thereof. It is to be understood for thc purposc of invention that Desvenlafaxine Benzoate may be present in the form of solvates with organic solvents like ethanol, isopropanol or hydrate like monohydrate, dihydrate or enantiomers.

It is to be understood for the purpose of ion, lfaxine Benzoate can be prepared by methods disclosed in Indian Patent Application no. 0761/KOL/2011 are hereby incorporated in its entirety.

In another embodiment, Desvenlafaxine Benzoate is in crystalline form characterized by a powder X-ray diffraction pattern having at least one peak at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 i 0.2 degrees 29 substantially as depicted in Figure 1.

In r embodiment, Desvenlafaxine Benzoate is in crystalline form characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 i 0.2 degrees 26 substantially as depicted in Figure 1.

In another ment, Desvenlafaxine Benzoate is in crystalline form characterized by a powder X-ray diffraction n having peaks at about 5.4, 9.5, 10.75, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 23.32 i 0.2 degrees 29 substantially as depicted in Figure 1.

W0 2012/140577 In another embodiment, Desvenlafaxine Benzoate is in crystalline form characterized by a powder X~ray diffraction pattern substantially in accordance with Figure 1.

More ably, Desvenlafaxine te is in crystalline form characterized by a powder X—ray diffraction pattern having peaks at about 5.4, 9.5, 10.7, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 21.5, 23.3, 24.9, 28.3, 29.9 i 0.2 degrees 29.

Desvenlafaxine Benzoate has solubility in water of greater than 30mg/ml, preferably the aqueous solubility of the Desvenlafaxine Benzoate is at least about 50 mg/ml at 250 C, more preferably, the aqueous solubility of Desvenlafaxine te is about 60 mg/ml at ° c.

Desvenlafaxine Succinale has lity in water of r than 30mg/ml, preferably the aqueous solubility of the Desvenlafaxine Succinate is about 35 mg/ml at 250 C.

Desvenlafaxine used in pharmaceutical compositions of invention in an amount of which is safe, well ted in patients with acceptable adverse effect es and are those in common practice and known to person skilled in the art.

Desvenlafaxine used to treat or prevent central nervous system disorders including, but not limited to depression ding but not limited to major depressive disorder, bipolar disorder and dysthymia), fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety er, generalized anxiety disorder, autism, phrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette me, tor flushing, cocaine and alcohol addiction, sexual dysfunction, (including premature ejaculation), borderline personality disorder, chronic fatigue syndrome, incontinence (including fecal incontinence, w incontinence, passive incontinence, reflex incontinence, stress urinary incontinence, urge incontinence, urinary exertional incontinence and urinary inence), pain (including but not limited to migraine, chronic back pain, phantom limb pain, central pain, neuropathic pain such as diabetic neuropathy, and postherpelic neuropathy), Shy Drager WO 40577 can also be used for preventing relapse or recurrence of depression; to treat cognitive impairment; for the inducement syndrome, d's syndrome, Parkinson's Disease, epilepsy, and others. Compounds and compositions of the present invention of cognitive enhancement in patient suffering from senile dementia, Alzheimer’s disease, memory loss, amnesia and a syndrome; and in regimens for cessation of smoking or other tobacco uses.

The dosage amount useful to treat, prevent, inhibit or alleviate each of the aforementioned conditions will vary with the ty of the condition to be treated and the route of administration. The dose and dose frequency will also vary according to age, body weight, se and past medical history of the individual human patient.

Dosage is bed in terms of the free base and is ed accordingly for the phamiaceutically acceptable salts. ln managing the patient, is generally preferred that the therapy be initiated at a lower dose and increased if necessary. Dosages for non-human patients can be adjusted accordingly by one skilled in the art, A modified release pharmaceutical composition according to the invention comprises but is not limited to tablets (single layered tablets, multilayered tablets, mini tablets, esive tablets, caplets, matrix tablets, tablet within a tablet, mucoadhesive tablets, modified e tablets, ile release tablets, and timed release tablets), s, beads, granules, ned release formulations, capsules, microcapsules, tablets in es, microspheres, matrix formulations, microencapsulation.

The term "modified release" used in pharmaceutical compositions of invention means controlled release, extended release, sustained release, delayed release or combination of any of these techniques. In other words, modified release pharmaceutical composition of inventions may be any formulation technique n release of the active substance from the composition is modified to occur at a slower rate than that from an immediate release composition.

In one embodiment, a ed e pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more ceutically acceptable excipient(s) thereof.

In another embodiment, a modified e pharmaceutical composition comprising Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipients(s) f.

In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

In another embodiment, a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

In another embodiment, a modified release pharmaceutical composition sing crystalline form of Desvenlafaxine Benzoate Characterized by a powder X-ray ction 1.5 pattern having at least one peak at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 i- 0.2 degrees 29 substantially as depicted in Figure 1. one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

In another embodiment, a modified release pharmaceutical composition sing crystalline form of Desvenlafaxine Benzoate terized by a powder X—ray diffraction pattern having peak at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 i 0.2 degrees 20 substantially as depicted in Figure 1, one or more release modifying agent(s) and one or more ceutically acceptable excipient(s) thereof.

In another embodiment, a modified release ceutical composition comprising crystalline form of Desvenlafaxine Benzoate characterized by a powder X-ray diffraction pattern having peaks at about 5.4, 9.5, 10.75, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 23.32 i 0.2 degrees 20 substantially as depicted in Figure 1, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

PCT/182012/051761 In another embodiment, a modified release pharmaceutical composition comprising crystalline form of Desvenlafaxine Benzoate characterized by a powder X—ray diffraction pattern substantially in accordance with Figure 1, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

In another embodiment, a ed release pharmaceutical composition comprising Desvenlafaxine te in crystalline form characterized by a powder X—ray diffraction pattern having peaks at about 5.4, 9.5, 10.7, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 21.5, 23.3, 24.9, 28.3, 29.9 i 0.2 degrees 20, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

In another embodiment, a modified e pharmaceutical composition comprising amorphous form of Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

In another embodiment, a modified release pharmaceutical composition sing Desvenlafaxine glutarate, one or more release modifying s) and one or more pharmaceutically acceptable excipientts) thereof.

In another embodiment, a modified release pharmaceutical ition comprising Desvenlafaxine palmitate. one or more release ing agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

The rel ease modifying agent(s) is hydrophilic, hydrophobic or combinations thereof.

In r embodiment, a modified e pharmaceutical composition comprises Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein release modifying s) is from about 1 % to about 95 % based on total weight of composition.

In another embodiment, a modified release pharmaceutical composition comprises Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more ceutically acceptable excipient(s) thereof wherein e modifying agent(s) is present in an amount less than about 55% based on total weight of composition.

In another embodiment, a ed release ceutical composition comprises Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more phannaceutically acceptable excipient(s) thereof wherein release modifying agent(s) is from about I % to about 95 % based on total weight of composition.

The hydrophilic e modifying agent(s) according to invention comprises but not limited cellulose derivatives, alginic acid derivatives, ccharides. alkylene oxides or mixtures thereof. ably, hydrophilic release modifying agent(s) comprises celluloses or their salts or derivatives thereof, hydroxyethylcellulose, ypropyl cellulose, hydroxypropyl methylcellulose (hyprornellose), sodium carboxymethyl cellulose, c acid or their salts and derivatives thereof, carbomer (Carbopol(TM)), polyethyleneoxide, xanthan gum, guar gum, locust bean gum, poly Vinyl acetate, polyvinyl alcohol, lactose.

The hydrophobic release modifying agent(s) according to the invention comprises but not limited to enated vegetable oils, polymethacrylates, ethyl cellulose or mixtures thereof.

Preferably, hydrophobic release modifying agent(s) comprises o methacrylate copolymers type A and B as described in USP, methacrylic acid copolymer type A, B and C as bed in USP, Polyacrylate dispersion 30% as bed in Ph. Eur., Polyvinyl acetate dispersion, ethylcellulose, cellulose acetate, cellulose propionate (lower, medium or higher lar weight), ose acetate propionate, ose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, ethyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), and poly(hexyl methacrylate). sodecyl methacryl ate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl actylate), poly(octadecyl te), waxes such as beeswax, carnauba wax, microcrystalline wax, and ozokerite; fatty alcohols such as cetostearyl alcohol, stearyl alcohol; cetyl alcohol and myristyl alcohol; and fatty acid esters such as glyceryl monostearate, glycerol distearate; glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, glyceryl behenate, and hydrogenated castor oil. 2012/051761 The average particle size of the particles of Desvenlafaxine or a pharmaceutically acceptable salt thereof, in the modified release ceutical composition of the invention is between about 5 microns to about 120 microns, preferably between about 7 microns to about 100 microns and more preferably about 10 microns to about 80 microns.

The terms "average particle size", "dso" and "mass mean diameter" can be used interchangeably.

The e particle size, i.e. the average equivalent diameter, is defined as the er where 50 mass % of the particles of the Desvenlafaxine have a larger equivalent diameter, and the other 50 mass—% have a smaller equivalent diameter.

The "average particle size" also refers to the median le diameter based on mass (i.e. the particle diameter where one half of the mass of particles is contributed by particles with a lesser diameter and one half of the mass of particles is contributed by particles with a r er).

The particle size can be ed using various commonly available methods such as measurement using light (eg. light—scattering methods or turbidimetric methods), sedimentation methods (eg. pipette analysis using an Andreassen pipette, sedimentation scales, photo—sedimentometers or sedimentation in a centrifugal force), pulse methods (eg. Coulter counter), or sorting by means of gravitational or centrifugal force.

It is to be understood for the purpose determining particle size of Desvenlafaxine or pharrnaceutically acceptable salts like Succinate or Benzoate in pharmaceutical compositions, the methods comprising but not d to isolating, crushing, extracting, separating and precipitating can be commonly employed. Determining particle size of Desvenlafaxine or pharmaceutically acceptable salts like ate or Benzoate in pharmaceutical compositions is well Within the scope of present invention.

In another ment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more ceutically acceptable excipient(s), wherein dso particle size of Desvenlafaxine is upto about 80 microns.

In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein dso particle size of Desvenlafaxine te is from about 10 microns to about 80 microns.

In another embodiment, a modified release ceutical composition sing Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more pharmaceutically able excipient(s), wherein dso particle size of Desvenlafaxine Succinate is upto about 80 microns.

In another embodiment, a modified release ceutical composition comprising Desvenlafaxine ate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein (150 particle size of Desvenlafaxine Succinate is upto about 50 microns.

In another embodiment, a modified release ceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying s) and one or more ceutically acceptable excipient(s).

In another embodiment, a modified release ceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable ent(s), such that dso particle size of Desvenlafaxine is upto about 80 microns.

In another embodiment, a modified release ceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically W0 2012/140577 acceptable excipient(s), wherein release of Desvenlafaxine is predominantly modified by coating.

In another embodiment, a modified release pharmaceutical composition having release of Desvenlafaxine in two or more steps at different release rates, which comprises a) a modified release part A comprising Desvenlafaxine, one or more release modifying agent(s) and one or more ceutically acceptable excipient(s) and b) a modified release part B comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s).

In another embodiment, a modified release pharmaceutical ition having release of Desvenlafaxine in two or more steps at ent release rates, which comprises a) a ed release part A comprising Desvenlafaxine, one or more release modifying s) and one or more pharmaceutically acceptable ent(s) and b) a modified release part B comprising lafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein part A is coated with part B.

In another embodiment, a modified release ceutical composition is bi—layer tablet ses a sustained release layer comprising Desvenlafaxine, one or more e modifying agent(s) and one or more pharmaceutically acceptable excipient(s); and immediate release layer comprising Desvenlafaxine and one or more pharmaceutically acceptable excipient(s).

In another embodiment, a modified release ceutical composition is multi-layered tablet. ln r embodiment, a modified release ceutical composition comprises a inert core which is loaded with drug layer comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein lafaxine Benzoate layer being further coated with one or more release modifying layer comprising release modifying agent(s) and one or more pharmaceutically acceptable excipient(s).

In another embodiment, a modified release pharmaceutical composition comprises a inert 3O core which is loaded with drug layer comprising Desvenlafaxine Succinate, one or more release ing agent(s) and one or more pharmaceutically acceptable excipient(s) 2012/051761 wherein Desvenlafaxine Succinate layer being further coated with one or more release modifying layer comprising release modifying agent(s) and one or more pharmaceutically acceptable excipient(s).

The inert core comprises but not limited to sugar sphere or pellets, microcrystalline cellulose sphere, sugar/starch core or any suitable material.

In r embodiment drug layer and release modifying layer may be separated by one or more separating layers.

The separating layer comprises one or more pharmaceutically able excipients and one or more hydrophilic agent(s), hydrophobic agent(s) or combination thereof.

The hilic agent(s) according to invention comprises but not limited to cellulose derivatives, c acid derivatives, polysaccharides, alkylene oxides or mixtures thereof.

Preferably, hydrophilic agent(s) ses celluloses or their salts or derivatives thereof, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl cellulose (hypromellose), sodium carboxymethyl ose, alginic acid or their salts and derivatives thereof, carbomer (Carbopol(TM)), polyethyleneoxide, xanthan gum, guar gum, locust bean gum, poly vinyl acetate, polyvinyl alcohol, lactose.

The hobic agent(s) according to the invention comprises but not limited to hydrogenated vegetable oils. polymethacrylates, ethyl cellulose or mixtures thereof.

Preferably, hydrophobic agent(s) comprises Ammonio methacrylate copolymers type A and B as described in USP, methacrylic acid copolymer type A, B and C as described in USP, Polyacrylate dispersion 30% as described in Ph. Eur., Polyvinyl acetate dispersion, ethylcellulose, cellulose e, cellulose nate (lower, medium or higher molecular weight), cellulose acetate nate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), thyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), and poly(hexyl rylate).

Poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(niethyl acrylate), poly(isopropyl acrylate), poly(isobutyl actylate), poly(octadecyl acrylate), waxes such as beeswax, carnauba wax, microcrystalline wax, and ozokerite; fatty alcohols such as cetostearyl l, stearyl alcohol; cetyl alcohol and myristyl alcohol; and fatty acid esters such as glyceryl earate, glycerol distearate; glycerol monooieate, acetyiated monoglycerides, arin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, yl behenate, and hydrogenated castor oil.

The term ‘pharmaceutically acceptable excipient(s)’ used in pharmaceutical compositions of invention comprise but not limited to diluents, binders, pH stabilizing agents, disintegrants, surfactants, glidants and ants.

The amounts of excipient(s) employed will depend upon how much active agent is to be used. One excipient(s) can perform more than one function.

Binders as used in the invention comprises but are not limited to, starches such as potato starch, wheat . corn starch: microcrystalline cellulose such as products known under the ered trademarks , Filtrak, Heweten or Pharmacel; celluloses such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose (HPMC), ethyl cellulose, sodium carboxy methyl cellulose; natural gums like acacia, alginic acid, guar gum; liquid glucose, dextrin, povidone, syrup, polyethylene oxide, polyvinyl pyrrolidone, poiy—N—vinyl amide, polyethylene glycol, gelatin, poly propylene glycol, tragacanth, combinations thereof and other materials known to one of ordinary skill in the art and mixtures thereof.

Fillers or diluents, as used in the invention comprises but not limited to confectioner’s sugar, compressible sugar, dextrates, dextrin, dextrose, fructose, lactitol, mannitol, sucrose, starch, lactose, xylitol, ol, talc, microcrystalline cellulose, calcium carbonate, calcium phosphate dibasic or tribasic, calcium sulphate, and the like can be used, Lubricants as used in the invention comprises but not limited to Mg, Al ,Ca or 7.n stearate, polyethylene glycol, yl behenate, mineral oil, sodium stearyl fumarate, stearic acid, hydrogenated vegetable oil and talc.

Glidants comprises but not limited to, silicon e; ium trisilicate, ed cellulose, starch, talc and tribasic calcium phosphate, calcium silicate, magnesium silicate, colloidal n dioxide, silicon hydrogel and other materials known to one of ordinary skill in the art.

Disintegrants comprises but not limited to starches; clays; celluloses; alginates; gums; cross—linked polymers, e.g., cross—linked polyvinyl idone or crospovidone, e.g., POLYPLASDONE XL, cross—linked sodium carboxymethylcellulose or croscarmellose sodium, e.g., AC—Dl-SOL from FMC; and linked m carboxymethylcellulose; soy polysaccharides; and guar gum. Use of disintegrant according to the ion facilitates in the e of drug in the latter stage and thereby completely releasing the drug from the dosage form.

The pharmaceutical composition may optionally contain a surface—active agent. The preferred agent is copolyrners composed of a central hydrophobic chain of polyoxypropylene (poly (propylene oxide» and polyoxyethylene (poly (ethylene oxide» that is well known as poloxamer. However, other agents may also be employed such as dioctyl sodium sulfosuccinate (DSS), triethanolamine, sodium lauryl sulphate (SLS), polyoxyethylene sorhitan and poloxalkol derivatives, quaternary ammonium salts or other pharmaceutically acceptable surface-active agents known to one ordinary skilled in the art, The pharmaceutical ition can be formed by various processes known in the art but not limited to such as by dry granulation, wet granulation, melt ation, direct compression, double compression, extrusion spheronization, layering and the like. The solvent(s) used in wet granulation include all the solvents well known in the art or the mixtures f.

In another embodiment, a modified pharmaceutical ition of invention comprises one or more coating comprising but not limited to modified e coating, sustained e coating, extended release coating, enteric coating, partial enteric coating or leaky enteric coating, bioadhesive coating and similar coatings known in the art. These coatings may help the pharmaceutical composition to release the drug at and for the required time.

These coatings se coating agent(s) selected from hydrophilic or hydrophobic agent(s) or the combinations thereof.

The hydrophobic agent(s) in the coating comprises but not limited to Ammonio 3O methacrylate copolymers type A and B as described in USP, methacrylic acid copolymer type A, B and C as described in USP, Polyacrylate dispersion 30% as described in pH.

Eur" Polyvinyl acetate dispersion, ethylcellulose, cellulose acetate, cellulose nate , medium or higher molecular weight), cellulose acetate nate, cellulose acetate butyrate; cellulose acetate ate, cellulose tn'acetate, poly(methy1 methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), and exyl methacrylate). Poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobuty1 actylate), ctadecyl acrylate), waxes such as beeswax, carnauba wax, microcrystalline wax, and ozokerite; fatty alcohols such as cetostearyl alcohol, stearyl alcohol; cetyl alcohol and myristyl alcohol; and fatty acid esters such as glyceryl monostearate, glycerol rate; glycerol eate, acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, glyceryl behenate, and hydrogenated castor oil.

The hilic agent(s) in the coating comprises but not limited to celluloses or their salts or derivatives thereof, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose), sodium ymethyl cellulose, alginic acid or their salts and derivatives thereof, carbomer pol(TM)), hyleneoxide, xanthan gum, guar gum, locust bean gum, poly vinyl acetate, polyvinyl alcohol, lactose, PVA these hydrophilic polymers also act as pore forming agent.

These coating comprises one or more excipients selected from the group comprising coating agents, opacifiers, taste~masking agents, fillers, polishing agents, colouring agents, antitacking agents and thc like.

The pharmaceutical composition can be coated by a wide variety of methods. Suitable methods include ssion coating, coating in a fluidized bed or a pan and hot melt (extrusion) coating. Such methods are well known to those skilled in the art.

In another embodiment, a stable modified release pharmaceutical composition comprising Desvenlafaxine, one or more release ing agent(s) and one or more pharmaceutically acceptable excipient(s) thereof.

In another embodiment, a modified e pharmaceutical composition comprising Desvenlafaxine, one or more e modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at l00 rpm.

In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Succinate, one or more release modifying agent(s) and one or more ceutically acceptable excipient(s), wherein composition releases about 75% of Desvenlafaxine Succinate in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.

In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine, one or more release modifying agent(s) and one or more phannaccutically acceptable excipient(s), wherein dsu particle size of Desvenlafaxine is upto about 80 s such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution tus in 900 ml of 0.9% NaCl in water at 100 rpm.

In another embodiment, a modified e pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein dso particle size of Desvenlafaxine Benzoate is from about 5 microns to about 80 microns such that composition es about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm. in another ment, a ed release pharmaceutical composition comprises from about 10 % to about 50% by weight of Desvenlafaxine ate and less than about 60 % of release modifying agent(s) based upon total weight of composition, wherein dso particle size of Desvenlafaxine Succinate is upto about 50 microns such that ition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I ution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.

In another embodiment, a modified release pharmaceutical composition comprises a 3O matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further PCT/IBZOIZ/051761 coated with one or more release modifying agent(s) and one or more pharmaceutically able excipient(s) wherein composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I dissolution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.

In another embodiment, a modified release pharmaceutical composition comprises a matrix core comprising Desvenlafaxine, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) wherein the matrix core being further coated with one or more release modifying agent(s) and one or more pharmaceutically acceptable ent(s), n dsg particle size of Desvenlafaxine is upto about 80 microns such that composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type I ution apparatus in 900 ml of 0.9% NaCl in water at 100 rpm.

In another embodiment of the invention is a method of lowering the incidence of nauseau, vomiting, diarrhea, abdominal pain, headache, agal malaise, and/or trismus resulting from the oral administration of venlafaxine, Desvenlafaxine, or a salt of Desvenlafaxine other than Desveniafaxine Benzoate to a patient. The method includes orally administering to a patient in nccd thereof a therapeutically effective amount of Desvenlafaxine te.

In another embodiment of the invention is a method of lowering the incidence of nausea, vomiting, diarrhea, abdominal pain, headache, vaso—vagal e, and/or trismus resulting from the oral administration of Desveniafaxine te to a patient. The method includes orally administering to a patient in need thereof a therapeutically effective amount of a sustained release oral dosage form comprising lafaxine Benzoate having a peak blood plasma level of less than about 225 ng/ml. lafaxine Benzoate may also be provided in combination with venlafaxine. The dosage of venlafaxine is preferably about 75 mg to about 350 mg/day and more preferably about 75 mg to about 225 mg/day. Still more preferably the dosage of venlafaxine is about 75 mg to about 150 mg/day. The ratio of Desvenlafaxine to venlafaxine will vary from patient to patient depending upon a t‘s response rate, but lly will be at least 6:1 Desvenlafaxine to venlafaxine.

Desvenlafaxine Benzoate is less fluffy than that of Desvenlafaxine Succinate. So, the g is less during manufacturing of the drug product and which gives ease of handling the drug nce as compared to the Succinate and there is a minimum chance of drug loss during manufacturing process and hence gives an advantage over Succinate salt.

Further, the particle size distribution of Desvenlafaxine Benzoate drug substance is smaller as compared to Desvenlafaxine Succinate drug substance. Hence, the distribution of drug substance in the drug t is uniform and gives no chance of variation in content uniformity of the final drug product/dosage form.

Due to its advantegeous properties, lower concentration of rate lling polymers or release modifying polymers is required for Desvenlafaxine Benzoate as compared to Desvenlafaxine Succinate in matrix tablet formulation to achieve the similar drug release profile and also to make the bioequivalent product with Pristiq®.

Pristiq® is the brandname for the extended release composition of Desvenlafaxine ate 50 mg and 100 mg marketed by Wyeth Pharmaceuticals Inc. (Now Pfizer) Philadelphia, PA 19101.

In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release ing agent(s) and one or more pharmaceutically able excipient(s), wherein the ed release composition provides Cmax (peak plasma levels) of upto about 225 ng/ml.

In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more e modifying agent(s) and one or more pharmaceutically acceptable ent(s), wherein the modified release composition provides C"lax (peak plasma levels) of upto about 300 ng/ml.

In another ment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof, wherein Cmax and AUC of the modified release composition are within the limit of 80 % to 125 % of Cmax and AUC of the extended e composition of Desvenlafaxine Succinate.

The term "Cm" as used herein, means maximum plasma concentration of lafaxine produced by the ingestion of the modified release composition of ion or the marketed I’ristiq® (Extended Release Composition of Desvenlafaxine ate) composition. Cmax or peak plasma level may be used interchangeably.

The term "AUC" as used herein, means area under the plasma concentration—time curve of Desvenlafaxine produced by the ingestion of the modified release composition of invention or the marketed Pristiq® (Extended Release Composition of lafaxine Succinate).

In r embodiment, a modified release ceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof wherein, Tmax of the modified release composition is comparable to Tmax of the extended release composition of Desvenlafaxine Succinate.

The term "me" as used herein, means time to the maximum observed plasma concentration of Desvenlafaxine produced by the ingestion of the modified release composition of ion or the marketed Pristiq® (Extended e Composition of Desvenlafaxine Succinate).

In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof n, Tmax of the modified release composition is less than about 8 hours.

In another ment, Cmax and AUC were able for the modified release composition of Desvenlafaxine Benzoate when administered after a high—fat meal and under fasting condition as the ratios falls between 80-125%.

PCT/132012/051761 In another embodiment, a modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable ent(s) thereof wherein CW, and AUC of the ed release composition are independent of food effect.

In another ment, a ed release pharmaceutical composition sing lafaxine te, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s) thereof, which is bioequivalent to Pristiq® tablet in a bioavailability study in .

A modified release pharmaceutical composition of the present invention can be used to treat or prevent l nervous system disorders including, but not limited to depression (including but not limited to major depressive disorder, r disorder and dysthymia), fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania). social anxiety disorder, generalized y disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor g, cocaine and alcohol addiction, sexual dysfunction, (including premature ejaculation), borderline personality er, chronic fatigue syndrome, incontinence (including fecal incontinence, overflow inence, passive inence, reflex incontinence, stress urinary incontinence, urge incontinence, urinary exertional incontinence and urinary incontinence), pain (including but not limited to migraine, chronic back pain, phantom limb pain, central pain, ncuropathic pain such as diabetic neuropathy, and postherpetic neuropathy), Shy Drager can also be used for preventing relapse or recurrence of depression; to treat cognitive impairment; for the inducement syndrome, Raynaud's syndrome, Parkinson's Disease, epilepsy, and others.

Compounds and compositions of the present invention of cognitive enhancement in patient suffering from senile ia, Alzheimer‘s disease, memory loss. amnesia and amnesia syndrome; and in regimens for ion of smoking or other tobacco uses.

Additionally, nds and compositions of the present invention can be used for 3O treating hypothalamic amenorrhea in depressed and non-depressed human females.

The following examples are illustrative of the present ion, and the examples should not be ered as limiting the scope of this invention in any way, as these examples and other equivalents thereof will become apparent to those versed in the art, in the light of the present sure, and the accompanying claims.

X —RD Stability Study The X-ray diffraction pattern for Desvenlafaxine Benzoate was measured using X-ray diffractometer.

X—RD pattern for Desvenlafaxine Benzoate is depicted in Figure 1.

Example 1: S.N6 NAME or INGREDIENTS % _Intragranular IDibasic calcium phosphate/ 18 12 rystalline Cellulose NF Film Coatin- ied Water USP/ IPA/DCM - Procedure: 1. Aqueous/Non-aqueous granulation of Desvenlafaxine Benzoate, Hyprornellose and Dibasic calcium phosphate/ MCC using Povidone as .

Dry the granules at SOi-S°C till desired LCD is achieved.

@PP’N Add the Extragranular part and mix well.

Compress the granules using suitable punch tooling Aqueous /Non—aqueous film coating.

Example 2: S.NO. NAME OF INGREDIENTS % W/W H Desvenlafaxine Benzoate 36.58 Hypromeliose 20.00 Purified Water/IPA -s Dibasic calcium phosphate/ Microcrystalline Cellulose 17 82 Extra_ranular ll Magnesium Stearate/Stearic Acid 2.00 Release Modif in Coatin Hypromellose Ethyl cellulose 1 I M Film Coatin_ 13 Purified SP/IPA/DCM Procedure: 1. s /Non-aqueous granulation of Desvenlafaxine Benzoate, Hypromellose and Dibasic calcium phosphate/ MCC using Povidone as binder.

!J Dry the granules at 50i5°C till desired LCD is achieved Add the Extragranular part and mix well.

Compress the es using suitable punch tooling U! Non— Aqueous coating with a build up of 1—10%w/w.

Aqueous /Non-aqucous film coating.

Example 3: NAME OF INGREDIENT % W/W Intragranular Extra_ranular nHypromellose 18.30 Colloidal Silicon Dioxide 3.00 Film Coating y 2.50 Purified Water USP/ IPA/DCM ‘33 Procedure: 1. Aqueous /N0n-aqueous granulation of lafaxinc ate/Palmitate, Hypromellose and Dibasic calcium phosphate / MCC using Povidone as binder. 95‘8"?) Dry the granules at SOiS°C till desired LOT) is achieved.

Add the Extragranular part and mix well.

Compress the granules using suitable punch toolingl Aqueous /Non-aqueous film coating.

Example 4: Immediate release layer Desvenlafaxine Benzoate .Purified Water Dibasic calcium phosphate /1Microcrystalline— Colloidal Silicon Dioxide — Sustained release layer 7 Desvenlafaxine Benzoate 3170 Budragil or Ethylcellulose 2500 Pu1ified Water Dibasic calcium phosphate / Microcrystalline 1356 Cellulose Colloidal Silicon Dioxide 2.00 Film Coating Opadry 50 14 Purified Water USP/ M Procedure: Immediate e layer 1. Aqueous iNon-aqueous granulation of Desvenlafaxine Benzoate and c calcium phosphate/ MCC using Povidone as binder. 2. Dry the granules at 50i5°C till d LOD is achieved. 3. Add Colloidal Silicon Dioxide and Magnesium stearate and mix well.

Sustained release layer 1. Aqueous/Non—aqueous ation of Desvenlafaxine Benzoate, Dibasic calcium phosphate / MCC using Methacrylic acid or Ethylcellulose as sustained release polymer. 2. Dry the granules at 50i5°C till desired LOD is ed 3. Add Colloidal Silicon Dioxide and Magnesium stearate and mix well. 4. Compress both the layers of Immediate and Sustained e part using le punch tooling.

U1 . Aqueous /Non—aqueous film coating.

Example 5: Film Coating -Purified Water USP/ IPA/DCM Procedure: 1. Desvenlafaxine Succinate and Hypromellose or Xanthum gum are dry mixed. 2. Add Microcrystalline Cellulose / Dibasic m phosphate to step 1 and mix well. 3. Add Colloidal Silicon Dioxide to Step 3 and mix well. 4. Lubricate the blend with Stearic acid or Magnesium Stearate.

. Compress the granules using suitable punch tooling. 6. Aqueous {Non—aqueous film g.

Example 6: NAMEOFINGREDIENTS % —Intragranular II-Microelystalline Cellulose_xtra;lanula1 II—I Release Modif1n_ Coatin; mellose -O5 Ethyl cellulose 1 1 IPA/DCM -S Film Coatin Purified Water USP/ IPA/DCM Procedure: 1. Aqueous /Non-aqueous granulation of Desvenlafaxine Succinate, Hypromellose and Dibasic m phosphate/ MCC using Povidone as binder. 2. Dry the granules at 50i5°C till desired LOD is achieved. 3. Add the Extragranular part and mix well, 4. Compress the granules using suitable punch g . Non- Aqueous coating with a build up of 1—10%w/w. 6. Aqueous /Non-aqueous film coating.

Example 7: NAME OF INGREDIENT % Desvenlafaxine Succinate Purified Water - Dibasic calcium phosphate / Microcrystalline 11.50 Cellulose -Colloidal Silicon Dioxide - Part-B Desvenlafaxine ate nEudiagit or Ethylcellulose ied Water Dibasic calcium phosphate / Microcrystalline 1356 -Colloidal Silicon Dioxide W0 2012/140577 Opadry Purified Water USP/ lPA/DCM Procedure: Part A 1. s queous granulation of Desvenlafaxine Succinate and Dibasic calcium phosphate/ MCC using Povidone as binder. 2. Dry the granules at SOiSOC till desired LOD is achieved. 3. Add dal Silicon Dioxide and Magnesium stearate and mix well.

Part B 4. Aqueous ueous granulation of Desvenlafaxine Succinate, Dibasic calcium phosphate / MCC using Methacrylic acid or Ethylcellulose as sustained release Dry the granules at SOiSOC till desired LOD is achieved Add Colloidal Silicon Dioxide and Magnesium stearate and mix well.

Compress both the layers of Part A and Part B part using suitable punch tooling. 9°99?" Aqueous /Non-aqueous film coating.

Example 8: W0 2012/140577 Film Coating nOpadry —02 ed Water USP/ lPA/DCM Procedure: 1. Desvenlafaxine Succinate and Ethyl Cellulose are dry mixed. 2. Add Microcrystalline Cellulose / Dibasic calcium phosphate to step 1 and mix well. 3. Add Colloidal Silicon Dioxide to Step 3 and mix well. 4. Lubricate the blend with Stearie acid or ium Stearate.

. Compress the granules using suitable punch tooling. 6. Aqueous /Non—aqueous film coating.

Example 9:I SN NAMEoF INGREDIENT ugar Hardening I» DCM/IPA Total Urug Loading Procedure — 1. Hardening of sugar spheres carried out. 2. Mix lafaxine Succinate, HPMC, talc & Aerosil. 3. Coat the mixture of Step 2 on sugar spheres of step 1 using DCM/IPA solution to form drug layer. 4. e Modifying coating of HPMC, ethyl cellulose, tale and triethyl citrate loaded on Drug layer of Step 3.

Example 10: Extragranular Microcrystalhne Cellulose c Acid _ a,ilm Coating v —(1.5 l Procedure: 1. Non—aqueous granulation of Desvenlafaxine te and Hypromellose using Povidone as binder. 2. Dry the granules at 55i5°C till desired LOD is achieved. 3. Add the Extragranular part and mix well. 4. Compress the granules using suitable punch g . Aqueous film coating.

Example 11: Eyedients Intragranular 1 Desvenlafaxine Succinate 2 Hypromellose Microcrystalline 1.52 Cellulose 6 Colloidal Siliconi'3. 6 il i i Film g Procedure: 1. Non—aqueous granulation of Desvenlafaxine Succinate and Hypromellose using Povidone as binder. weww Dry the granules at 55i5°C till desired LCD is ed Add the Extra granular part and mix well.

Compress the granules using suitable punch tooling Aqueous film coating.

Example 12: I——gInn'agranular lafaxine 36 24 Succinate I Hypromellose _3 570 Colloidal Silicon Dioxide _ i l Ext;agr(mular r Colloidal ‘ e I _0.5.2.0 . n— ; Film Coating Opadry 2030 : Procedure: 1. Compact Desvenlafaxine Succinate, Hypromellose, Colloidal Silicon Dioxide, Talc and Magnesium Stearate in a roller compactor. 9:953!" Sift and size the granules using comminuting mill to desired granules size.

Add the Extragranular part and mix well. ss the granules using le punch tooling Aqueous film coating.

Example 13: -_edins" ' ' 7 7 Intragranular 1 Desvenlafaxine 3 7.56 ‘ Benzoatc 2 Hypromellose 000153000 Extragrauulm I—w1644Cellulose flDioxide WO 40577 Film Coating Purified water Procedure: 1. Compact lafaxine Benzoate, Hypromellose, Talc and Stearie Acid in a roller eompactor.

:PP’P Sift the granules using eomminuting mill to desired granules size.

Add the Extragranular part and mix well.

Compress the granules using suitable punch tooling . Aqueous film coating.

In-Vitro Dissolution Study: Table 1 given below shows the dissolution e of Desvenlafaxine Benzoate Modified Release s of Example 1 of the present invention carried out in 900 ml of 0.9% NaCl in water for 24 hours using Apparatus USP-I (Basket) at 100 rpm speed. The release profile (cumulative % of dmg released) is given in Table 1.

Table 1: umulative Drug Release For Example 1 -Not More Than 20% -Not Less Than 75% Table 2 given below shows the dissolution profile of Desvenlafaxine Suceinate Modified Release Tablets of e 5 of the present invention carried out in 900 ml of 0.9% NaCl in water for 24 hours using Apparatus USP-I (Basket) at 100 rpm speed. The release profile (cumulative % of drug released) is given in Table I.

Table 2: Time In Hrs tive % Drug Release For Example 5 Not More Than 20% "50% Not Less Than 75% In -Vivo Bioavailability Study: An Open Label, ed, Randomized, -Dose, Treatment, Three—Sequence, Three—Period Crossover Oral Bioequivalenee Study Of Reference product (Treatment A) PRISTIQ® (Extended release composition of Desvenlafaxine Suceinate) 100 mg of Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101 and Test product (Treatment B) Desvenlafaxine Benzoate Modified Release Tablet 100 mg formulated as per Example 13 under fasting conditions and food effect study of Desvenlafaxine Benzoate Modified Release Tablet 100 mg ated as per example 13 administered under fasting (Treatment B) and fed (Treatment C) conditions in Healthy, Adult, Human Male Subjects.

The study was designed to demonstrate the similar clinical efficacy compared to Pristiq®.

The va bioavailability study in fasting state shows the results as shown in the Table 3 below: Table 3: Comparative pharmacokinetic parameters of Example 13 vs Pristiq® 100 mg in Fasted state Tmax (hrs) ng. hr /ml 12g. hr /ml rig /mI ; Desvenlafaxine 5429.332 6140836 249.504 5.943 Benzoate MR Tablets 100 mg 51 263.630 6096.586 Conclusions: Bioequivalence between ent A and B stered under fasting conditions: The 90% Confidence Interval of the ve geometric mean of Cum, AUC(0.[) and AUC(0- m) were found to be within the limit of 80 % to 125 %. Based on the results obtained, lafaxine Benzoate Modified Release Tablet 100mg formulated as per Example 13 and PRISTIQ® (Extended release composition of Dcsvenlafaxine Sueeinatc) 100 mg of Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101, are found to be bioequivalent in healthy human adult male subjects under fasting conditions.

Food effect (Treatment B vs C) on Desvenlafaxine Benzoate ed Release Tablet 100mg: Administration of Desvenlafaxine Benzoate Modified Release Tablets 100 mg with food had a minimal effect on drug absorption, resulting in an approximate 2 hour delay in Tmax.

Cmm and AUC were comparable for Desvenlafaxine Benzoate Modified Release Tablets l00 mg when administered after 21 hi gh-fat meal and under g condition as the ratios falls between EEO-125%. Food is not expected to have significant al effect on the absorption (Cmax and AUC) of Desvenlafaxine from Desvenlafaxine Benzoate Modified Release Tablets 100 mg. Desvenlafaxine Benzoate Modified Release s 100 mg can be administered Without regard to food.

Claims (1)

1. CLAIMS 1. A modified release pharmaceutical composition comprising Desvenlafaxine Benzoate, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein Desvenlafaxine Benzoate is characterized by a powder X—ray diffraction n having peaks at about 5.4, 10.75, 16.6, 18.0, 19.2, 23.32 i 0.2 degrees 26. The modified release ceutical composition of claim 1, wherein Desvenlafaxine Benzoate is terized by powder X—ray diffraction pattern having peaks at about 5.4, 9.5, 10.7, 16.1, 16.6, 17.3, 18.0, 19.2, 20.4, 21.5, 23.3, 24.9, 28.3, 29.9 i 0.2 degrees The modified release pharmaceutical ition of claim 1, wherein said composition releases about 75% of Desvenlafaxine in 16 hours measured using USP Type i dissolution apparatus in 900 ml of 0.9% NaCl in water, at 100 rpm. The modified release pharmaceutical composition of claim 1, wherein Cmax and AUC of the modified release composition are within the limit of 80 % to 125 % of Cmax and AUC of the extended release composition of Desvenlafaxine ate. ‘ The modified release pharmaceutical composition of claim . 1, wherein Cmax and AUC of the modified release composition are independent of food effect. A modified e pharmaceutical composition according to claim 1, substantially as herein described with reference to any one of the accompanying es and or figure thereof. wo